Journal article icon

Journal article

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Abstract:

Myelodysplastic syndromes (MDSs) are a group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral blood cytopenias. Lenalidomide has dramatic therapeutic effects in patients with low-risk MDS and a chromosome 5q31 deletion, resulting in complete cytogenetic remission in >60% of patients. The molecular basis of this remarkable drug response is unknown. To gain insight into the molecular targets of lenalidomide we investigated its in vitro effects on...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1073/pnas.0610477104

Authors


Expand authors...
Journal:
Proceedings of the National Academy of Sciences of the United States of America
Volume:
104
Issue:
27
Pages:
11406-11411
Publication date:
2007-07-05
DOI:
EISSN:
1091-6490
ISSN:
0027-8424
URN:
uuid:0cf7a7e5-2ff0-4626-a234-f1877818f458
Source identifiers:
246233
Local pid:
pubs:246233

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP